AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comSEP 252 min read$CDNA

CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?

CareDx (CDNA) shares rose 13% to $61.37 on high volume, following a price target increase to $74 by BTIG. Q2 2026 revenue grew 52% YoY, with testing services up 61%. Q3 earnings are expected at $0.24 per share, down 14.3% YoY, and revenue at $122.35M, up 22.3% YoY. The stock has a Zacks Rank of #2 (Buy). Charles River Laboratories (CRL), another medical services company, closed up 6.2% at $294.44, with a Zacks Rank of #2 (Buy).

Original reporting
finance.yahoo.com
Published Sep 25, 2026, 7:18 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 8:44 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar? — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$CDNABullishMed
01

Why it matters

The upgrade could attract momentum traders, but lack of earnings estimate change may limit durability.

02

Market read

Short-term bullish catalyst for CDNA; peers may see modest spillover.

03

What to watch

No change in earnings estimates; the move relies solely on analyst opinion.

Relevance 7/10Novelty 7/10Timing: after-market today

Background

CareDx reported a 13% price increase after BTIG raised its target price, while revenue growth expectations remain strong.

Company-level read

Ticker impact

$CDNABullishMedium confidence
Context

BTIG raised its price target to $74 from $60, triggering a 13% intraday jump in CareDx shares.

Expected impact

Potential continued upside if momentum sustains, but limited by lack of new earnings data.

Evidence & confidence

Price target lift is fresh news; however, no earnings revision accompanies it, so move may be short-lived.

Market effects

Sector

Positive sentiment may spill to other molecular diagnostics stocks.

Regional

Limited to US biotech sector.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The price jump may be overbought without earnings support; caution on pullback.

Key entities

  • Company
    CareDx, Inc.

    Molecular diagnostics firm (ticker CDNA).

  • Analyst Firm
    BTIG

    Raised CareDx price target to $74.

Read at source← All news

Related articles

SEP 25
$CDNAMed

Biotech Stocks At 52-Week Highs - CDNA +13%, GRAL +15%, TWST +16%, ADPT, RVTY

Several biotech stocks hit 52-week highs on September 24, 2026. CareDx (CDNA) rose 13% to $63.09, Grail (GRAL) climbed 15% to $126.81, Adaptive Biotechnologies (ADPT) gained 6% to $29.58, Revvity (RVTY) increased 6% to $152.26, and Twist Bioscience (TWST) surged 16% to $185.22. Key catalysts included regulatory milestones, clinical trial results, and strategic acquisitions.

rttnews.com2 min
AUG 1
$CDNAMedAI 8/10

CareDx Q2 Earnings Call Highlights

CareDx (NASDAQ:CDNA) provided Q2 earnings call guidance. Full-year testing volume is forecast at 258,000 to 266,000 tests and testing-services revenue around $400 million, including $24 million specialty oncology. Patient and digital revenue is expected at $72 million, lab products $23 million, and non-GAAP gross margin 71% to 73%. The company also discussed Medicare LCD coverage, Q3 and Q4 test assumptions, and pipeline updates for AlloHeme and HistoMap.

yahoo.com6 min